Levicept Limited logo

Levicept Limited

Levicept: a novel biological for the treatment of chronic pain Levicept is a biopharmaceutical company focused solely on the preclinical and clinical development of p75NTR-Fc as treatment for osteoarthritis and chronic pain.

Levicepts lead molecule p75NTR-Fc was originally discovered at Pfizer by Levicepts founder and CEO, Simon Westbrook, who subsequently acquired the asset following the closure of Pfizers research site in Sep 2013.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.levicept.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Innovation HouseDiscovery ParkRams gate Road Kent CT13 9ND,
Sandwich
United Kingdom
Email
Contact Number
+44 75-9081-5398

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/levicept-ltd” connections=”true” suffix=””]

In 2014, Levicept raised £10 Mn in Series A financing from Advent Life Sciences, Gilde Healthcare and Index Ventures. In addition, it was awarded a £2.4 Mn grant from the Biocatalyst Fund of the UKs innovation agency, Innovate UK, in April 2014.